COVID-19 Impact on Pharmaceutical Packaging in Chemicals and Materials Industry

Collaboration between AstraZeneca and Mass General Hospital:

  • Uncategorized
  • Jul 07, 2021

Collaboration is one of the most important foundations to extract knowledge from any kind of source. The organization plans to work together actively and will use Astrazeneca's Amaze Disease Management platform to provide critical information. It will aid in how to manage the platform to provide high-level clinical patient insights and validate digital health solutions. Digital health solutions are modernized every day as announced by biotechnology. The Astrazeneca industry would be actively involved in the collaborative program being run with Massachusetts General Hospital, and that collaboration has good reason to create a patient-centric digital health solution very good environment and health and environment around you.

Sometimes there is a chance that the patient might not get their preferred treatment. To solve this problem, collaboration acts as a savior as it can provide you with the relevant treatment. Let's understand this collaboration framework by an example where a patient went to a hospital and could not find the treatment he/she wanted but other hospital’s doctors can do this if it is in collaboration.

This is a proud moment for the Astrazeneca industry as they will be collaborating and closely working with Massachusetts General Hospital to use this digital platform to its all extent. This digital platform can also be used to open up new opportunities and to close gaps in patient care for the healthcare industries and this is ultimately leading to better outcomes. Such new possibilities create more chances to develop something new with the help of positive collaborations. It is said by Rubb Dobber who is a president of the Biopharmaceuticals Business unit at AstraZeneca.

Patients will be enrolled in the study after an inpatient heart-failure admission at Massachusetts General Hospital. The organizations say the first two studies are aimed at piloting AMAZE in a real-world setting with the goal of improving patient engagement, care-team communication and clinical outcomes. They also hope to reduce healthcare costs in doing so. It is being believed that the AMAZE disease management platform has the potential to transform the current healthcare delivery paradigm for patients around the world living with chronic diseases. After the conclusion of the heart failure and asthma pilots, Massachusetts General and AstraZeneca say they plan to expand the use of AMAZE across multiple chronic disease areas to patients throughout and beyond the Mass General Brigham system.